Stories
Mostafa Kamal talks evolution of PBM industry, latest developments, in Fierce Healthcare panel
Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs
January 30, 2024Prime Therapeutics CEO and President Mostafa Kamal recently joined industry experts in a panel discussion about the evolving landscape of pharmacy benefit managers (PBMs).
On Jan. 18, Kamal joined moderators from Fierce Healthcare and panelists Adam Kautzner (President, Express Scripts), John O’Brien (President and CEO, National Pharmaceutical Council), and Anthony Loiacono (CEO, Capital Rx) in a panel entitled “Pharmacy Benefit Managers: The Evolving Discussion.”
“If you reflect on the history of PBMs, this industry has had an amazing track record of redefining itself every half a decade to decade, essentially to meet the emerging and evolving needs,” Kamal says. “I can’t think of a more exciting time to be in this industry. I think the innovation we’re seeing around pharmaceutical products creates a lot of hope.”
Experts explored the issues, changes and challenges impacting the role and influence of PBMs, delving into hot topics such as GLP-1 weight-loss drugs, biosimilars, rising pharmaceutical costs and the future of the PBM industry.
“With the proliferation of technology—artificial intelligence and other tools that we see emerging around us—I think it’s a unique moment in time for us to be able to look at the macro trends, identify significant needs and bring in technology to help us solve and move forward in ways that go beyond what we’ve done historically,” Kamal says, “which is managing unit costs and managing utilization, and move PBMs more toward managing total experiences and affordability and outcomes for patients—total health outcomes.”
Register for free to see the full panel discussion, then click on “Sessions” then “Panel: Pharmacy Benefit Managers: The Evolving Discussion | Closing Remarks.”
Related news
Stories
July 22, 2024
Introducing the latest issue of our medical and pharmacy benefit management report
The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care
Stories
July 18, 2024
Specialty drug trend forecasted to drop for employer groups, clinical experts say
Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend
Stories
July 16, 2024
Prime/Magellan Rx earns top score on the Disability Equality Index
For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion